Harvard Bioscience, Inc.
corporate_fare Company Profile
Harvard Bioscience, Inc. (NASDAQ:HBIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 28 items for HBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for HBIO spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Harvard Bioscience 10-Q: Q3 Loss Widens to $2.6M, Cash Falls to $4.9M With Going-Concern Review
- Harvard Bioscience Cuts FY26 Adjusted EBITDA Guidance to (1%)-4% From 6%-10%
- Harvard Bioscience Q3 Revenue Up 8% to $22.2M; Full-Year EBITDA Guidance Cut
- Harvard Bioscience Posts $0.58 Per-Share Q3 Loss
- Harvard Bioscience Lifts Full-Year Outlook as Q2 Revenue Climbs 11%
Financial Snapshot
Short Interest & Short Volume
3.50 days to coverFINRA reported short interest of 66,461 shares in HBIO as of the October 30, 2026 settlement, a 32.5% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 34.3% of HBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.